Articles tagged with Pharmacology
A novel approach combining chemotherapy, immunotherapy, and a MET inhibitor enhances treatment response and limits tumor growth in small cell lung cancer (SCLC). The strategy slows tumor progression and improves survival outcomes by facilitating the effectiveness of standard treatment.
BU researchers Hui Feng and Venetia Zachariou have received a $2.1 million NIH grant to fund a five-year training program in biomolecular pharmacology. The program aims to prepare the next generation of independent investigators through individualized and multidisciplinary research training.
A groundbreaking cancer drug, KCL-HO-1i, has shown promise in making chemotherapy-resistant cancers more responsive to therapy by targeting a key defence mechanism used by tumours. In preclinical models, the drug has already demonstrated effectiveness in laboratory tests using mouse models of breast cancer.
Researchers developed a deep learning model to predict ADRs using molecular structures, achieving high accuracy in detecting rare effects and minimal risk for novel molecules. The model demonstrated potential as a decision-support tool in early-phase drug discovery and regulatory safety monitoring.
A new study found antimicrobial resistant bacteria spreading rapidly among children with severe malnutrition in Niger. The bacteria can cause life-threatening infections like pneumonia and sepsis, which are difficult to treat with antibiotics.
Researchers validated panels of antibodies targeting clinically relevant nucleic acid modifications to visualize antisense oligonucleotides in both in vitro and in vivo studies. The tools enable detection of modified nucleic acids irrespective of sequence, facilitating multiple clinical and pre-clinical workflows.
Researchers conducted a randomized clinical trial to compare low- and high-dose methylprednisolone with azithromycin for treating severe Mycoplasma pneumoniae pneumonia. The study found that lower dose regimen of glucocorticoids is sufficient, equally effective, and safer than the high dose regimen.
A new treatment for corneal scarring is being developed by University of Houston optometry researcher Tarsis G. Ferreira. The treatment uses a natural protein called decorin to block scarring and unwanted blood vessel growth, offering hope for people with injured corneas.
Researchers discovered complex structures in millipede secretions that can modulate specific neuroreceptors in ant brains, shedding light on potential new medications. The newly found alkaloids, named andrognathanols and andrognathines, have shown potent interactions with the Sigma-1 neuroreceptor.
The 2025 Critical Path Institute Global Impact Conference will bring together industry, regulatory agencies, academia, and patient advocacy groups to discuss pressing challenges in drug development. The event aims to foster cross-sector collaboration to advance medical innovation and improve treatment outcomes for patients.
Research warns that GLP-1 drugs may not provide the long-term health benefit of improved heart and lung function. While they help with weight loss, patients may experience significant muscle loss, which can increase cardiovascular disease risk. Doctors are urging additional research to better understand the effects of these drugs.
Researchers aim to understand the role of blood vessels in traumatic brain injuries and their link to age-related cognitive impairment. They plan to use mice with a mutation in the UCH protein to explore how blocking this protein affects brain sugar processing and neurovascular function.
A new study has identified a gut microbiota-derived metabolite, imidazole propionate (ImP), that appears in the blood during the early stages of active atherosclerosis. The presence of ImP is associated with the development of active atherosclerosis in people who otherwise appear healthy.
Current Molecular Pharmacology seeks talented young professionals for its editorial board. The journal focuses on cellular and molecular pharmacology advancements, genomics, proteomics, and drug action mechanisms.
A review of 64 over-the-counter products found that omega-3s, St John's Wort, probiotics, and vitamin D have substantial evidence for treating depression. Other promising products include folic acid, lavender, zinc, tryptophan, and lemon balm. However, more research is needed to confirm their effectiveness and safety.
This special issue focuses on cutting-edge advancements in polypharmacology for cancer therapy, addressing mechanisms of drug resistance and rational design of drug combinations. It also covers computational and AI-driven methodologies for discovering novel polypharmacological agents.
Current Pharmaceutical Analysis seeks ambitious individuals to join its young editorial board, promoting pharmaceutical analysis development and enhancing academic influence. The journal focuses on multidimensional explorations in pharmaceutical analysis and pharmacological research.
A new study suggests Caligula was knowledgeable about medicine, particularly medicinal plants like hellebore, contrary to the traditional portrayal of him as a bloodthirsty tyrant. The Roman Empire's Antikyra spa town was renowned for its perceived efficacy in treating various ailments.
A study published in Science Advances found that repurposing FDA-approved drugs can enhance the safety of nanomedicines by blocking complement activation and minimizing adverse effects. The research identified iptacopan, a drug approved for rare blood disorders, as a promising candidate for improving immune responses to nanoparticles.
Researchers have identified a hidden molecular mechanism involving two proteins that allows tumors to resist treatment. A new gelatin-based nanoparticle has been developed to shut down both proteins simultaneously, showing promising results in early studies with mice.
Dr. Mirko Manchia's groundbreaking research identifies genetic markers predicting treatment response in bipolar patients, enabling precision medicine approaches to transform psychiatric care. He envisions a future where genetic testing becomes routine in psychiatric care.
Dr. Deanna L. Kelly has been named Director of the Maryland Psychiatric Research Center, building on her expertise in schizophrenia treatments and nutrition. She continues to advance personalized treatment options, including effective medications and innovative dietary interventions.
Researchers analyzed 13,000 gene donors' data to understand why some individuals experience more side effects from antidepressants. The study found that a genetic variant affecting metabolism and polygenic risk are associated with increased side effect occurrence.
A new study by University of Missouri researchers found that states granting full practice authority to APRNs significantly improves health outcomes and increases access to care. In contrast, restricted practice laws impose financial burdens on patients and limit APRN autonomy.
A special issue of Journal of Intensive Medicine provides key insights into selecting optimal non-invasive respiratory support strategies for AHRF, featuring review articles and original research. The collection offers guidance on the efficacy of HFNC, CPAP, NIV, and awake prone positioning to improve patient outcomes.
Researchers at Ruhr-University Bochum have discovered that hepatitis E viruses can infect kidney cells, leading to a potentially insurmountable challenge in treating the infection. The study found that infected kidney cells responded poorly to antiviral medication, suggesting the virus has evolved to evade treatment.
Dr. Danielle Beckman's research uses animal models to understand how viruses like COVID-19 trigger neurological damage and accelerate Alzheimer's disease. Her work has established critical connections between viral infections and neurodegenerative processes.
Researchers used computational simulations to investigate changes in synaptic connections during sleep-wake states. They found that synaptic connections are strengthened when specific levels of neural activity accompanied typical synaptic learning rules, enabling theoretical predictions of sleep learning conditions.
This study confirms Lycium barbarum contains multiple components that interact with various targets and pathways to treat liver cancer. The active ingredients have good binding ability, indicating a potential therapeutic effect.
Scientists have developed a method to produce macrocyclic peptides using brewer's yeast, which can be rapidly analyzed for therapeutic applications. The approach harnesses the natural machinery of yeast to create biocompatible and biodegradable peptide molecules with precision targeting and stability.
A new study from Karolinska Institutet found that biological drugs used to treat severe asthma do not completely eradicate inflammatory cells. Researchers discovered an increase in blood levels of these cells during treatment, which could explain why inflammation often returns when treatment is tapered or discontinued. The study aims t...
UVA Health received two anonymous $25 million estate gifts to support the Paul and Diane Manning Institute of Biotechnology. The institute will develop new treatments for hard-to-treat diseases with a state-of-the-art biomedical research facility expected to drive economic growth in Central Virginia.
The SEB Conference 2025 will feature over 500 talks on latest advances in experimental research across animal, plant and cell biology. The event highlights groundbreaking research in biomechanics, wildlife conservation, human disease and bio-inspired robotics.
A new gene therapy delivery device called NANOSPRESSO could revolutionize how hospitals treat rare diseases by allowing them to create personalized nanomedicines in-house. This democratized approach to precision medicine could boost access to low-cost bespoke gene and RNA therapies, especially in low-resource settings.
A new Center for Protein Design at the University of Copenhagen aims to create artificially designed proteins with tailored properties to tackle diseases, environmental issues, and industrial applications. The centre will drive fundamental research and translate basic findings into concrete solutions.
Research synthesizes evidence from dozens of studies on polygenic scores and their clinical implications, revealing consistent patterns that could contribute to personalized psychiatric care. Higher genetic risk for depression correlates with poorer treatment outcomes, including nonresponse to antidepressants and mood stabilizers.
A new study reveals that US Muslims show moderate openness to psychedelics in mental health therapy, with higher education correlating with favorable attitudes. Providing education about psychedelic therapies may help lower barriers to considering this treatment.
Researchers used nanomedicine and artificial intelligence to analyze plasma samples, identifying potential biomarkers for metastatic prostate cancer and atherosclerosis. This breakthrough discovery has the potential to advance early detection and develop targeted therapies for these conditions.
A new national guideline provides unified strategies for managing RSV infections in children under five, emphasizing rapid antigen detection, oxygen therapy, and pharmacological treatments. The guideline also supports the use of monoclonal antibodies and recommends non-pharmaceutical interventions to prevent pediatric RSV infections.
Scientists at Xi'an Jiaotong-Liverpool University developed a new nanoparticle capable of carrying high doses of chemotherapy drugs while staying stable for extended periods. This innovation could make treatments more effective and reduce side effects.
Researchers from Florida Atlantic University's Charles E. Schmidt College of Medicine aim to reduce falls and adverse drug events among older adults by using personalized approach tailored to individual genetic profiles.
Researchers discover iguratimod, a rheumatoid arthritis drug, effectively treats excessive COVID-19 inflammation in mice by maintaining antiviral immune responses. The study provides hope for patients with severe COVID-19-related cytokine storms.
Dr. Stephen Ross's groundbreaking studies using psilocybin therapy have demonstrated rapid, substantial, and sustained improvements in psychological symptoms for patients with advanced cancer, substance use disorders, and major depressive disorder. His research has the potential to challenge conventional psychiatric medication approaches.
Researchers review nanozymes derived from Chinese herbs, including their catalytic properties, biomedical applications, and potential challenges in developing herbzymes for practical use. The review highlights three main types of herbzymes: herb carbon dot enzymes, polyphenol-metal nanozymes, and herb extract nanozymes.
Dr. Deanna Kaplan's innovative voice-capture app, Fabla, captures unstructured voice narratives to study how clinical interventions influence daily life. The platform has found applications across diverse health domains, including veteran experiences and healthcare provider burnout.
Researchers used breath analysis to monitor general anesthesia in children, achieving results comparable to blood tests. The method also detected oxidative stress and potential complications, enabling early detection and prevention.
A pioneering research brings psychedelic medicine into gastroenterology, exploring psilocybin's effects on treatment-resistant irritable bowel syndrome (IBS). Dr. Erin E. Mauney's study modulates interoception and uses integrated therapy sessions with neuroimaging to track brain changes.
Dr. Nikolaos Koundouros has been awarded the 2025 Tri-Institutional Breakout Award for his research on how cells detect and respond to dietary nutrients, specifically omega-6 and omega-3 fatty acids, in relation to breast cancer development.
A new study has identified a way to target the viral enzyme uracil-DNA glycosylase (vUNG) that helps HSV-1 evade the immune system, allowing reactivation of APOBEC1 and improving survival in infected mice. This approach offers a promising therapeutic strategy for treating HSV-1 encephalitis by strengthening brain immunity.
The Phase 1 study of EBC-129 has shown encouraging signs of efficacy in heavily pre-treated pancreatic ductal adenocarcinoma patients, with an overall response rate of 25% and disease control rate of 87.5%. The drug also demonstrated a manageable safety profile, with no major treatment-related adverse events.
The Ochsner Health system implements pharmacogenomics to fine-tune treatments based on individual genetic profiles, transforming patient care through personalized medicine. Pharmacists play a pivotal role in spearheading these innovations, overcoming barriers and maximizing impact.
A WVU microbiology student has discovered a new species of fungus, Periglandula clandestina, that produces effects similar to the semisynthetic drug LSD. The fungus is highly efficient at making ergot alkaloids, which can be used therapeutically to treat conditions like depression and addiction.
Researchers from Florida Atlantic University have discovered a potentially safer treatment for multiple disorders linked to altered dopamine signaling by blocking the kappa opioid receptor. The study found that this approach can correct behavioral deficits and normalize dopamine availability.
The Experimental Drug Development Centre's EBC-129, an antibody-drug conjugate targeting pancreatic cancer, has received FDA fast track designation. The treatment is undergoing Phase 1 clinical trials and aims to provide new treatment options for patients with solid tumours.
Researchers found that an inexpensive HIV drug can improve vision in patients with diabetic macular edema (DME) more effectively and at a lower cost than existing treatments. The drug, lamivudine, is taken orally and may represent a game-changing option for millions of patients worldwide.
Seven Clusters of Excellence at LMU Munich have been approved for funding, covering a broad range of fields from systems neurology to quantum science. The successful clusters reflect the university's exceptional commitment and cooperation with partners.
A new protocol has been developed to establish a safer standard for medication use during breastfeeding. The study focuses on the concentration of prednisolone and metformin in breast milk and infant plasma, addressing a significant knowledge gap in human lactation studies.
Scientists have identified a brain molecule called NEAT1 that appears to play a central role in triggering light sensitivity (photophobia) during migraines. By disrupting the normal balance of nerve signaling and pain regulation, NEAT1 makes nerves more sensitive to light.
A group of doctors has filed a complaint with the National Institutes of Health's Office of Laboratory Animal Welfare, alleging that Arizona State University used mice in a study on dietary supplements and adults with Down syndrome. The experiment involved invasive procedures and was deemed scientifically unjustifiable by experts.
The Center for Research Innovation in Biotechnology (CRIB) has developed a comprehensive database of active pharmaceutical ingredients with evidence of clinical testing. The database provides valuable information on drug discovery and development, including pricing, sponsors, and intended clinical applications.